Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ran Reshef

Showing results (101-110 of 144) with videos related to

Pageof 15
Sort By:
Blood Advances|May 4, 2023
The utility of biomarkers in acute GVHD prognosticationNikolaos Spyrou, Yu Akahoshi, Francis Ayuk, et al.
JCI Insight|February 15, 2017
An early-biomarker algorithm predicts lethal graft-versus-host disease and survivalMatthew J Hartwell, Umut Özbek, Ernst Holler, et al.
Transplantation and Cellular Therapy|September 27, 2025
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease SeverityIoannis Evangelos Louloudis, Yi-Bin Chen, Nikolaos Spyrou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2017
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell TransplantationRobert J Soiffer, Haesook T Kim, Joseph McGuirk, et al.
The New England Journal of Medicine|June 21, 2023
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease ProphylaxisJavier Bolaños-Meade, Mehdi Hamadani, Juan Wu, et al.
Transplantation and Cellular Therapy|September 2, 2024
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White PatientsCarlos A Ortega Rios, Muna Qayed, Aaron M Etra, et al.
Blood Advances|April 20, 2022
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratificationAaron Etra, Stephanie Gergoudis, George Morales, et al.
Leukemia|February 6, 2020
Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplantMina D Aziz, Jay Shah, Urvi Kapoor, et al.
Blood Advances|April 30, 2025
Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703Sameem M Abedin, Michael J Martens, Javier Bolaños-Meade, et al.
JCI Insight|August 24, 2018
An early-biomarker algorithm predicts lethal graft-versus-host disease and survivalMatthew J Hartwell, Umut Özbek, Ernst Holler, et al.
Pageof 15

Showing results (101-110 of 144) with videos related to

Sort By:
Pageof 15
Blood Advances|May 4, 2023
The utility of biomarkers in acute GVHD prognosticationNikolaos Spyrou, Yu Akahoshi, Francis Ayuk, et al.
JCI Insight|February 15, 2017
An early-biomarker algorithm predicts lethal graft-versus-host disease and survivalMatthew J Hartwell, Umut Özbek, Ernst Holler, et al.
Transplantation and Cellular Therapy|September 27, 2025
Performance of Treatment Response Assessment at Day 7 by Baseline Acute Graft-versus-Host Disease SeverityIoannis Evangelos Louloudis, Yi-Bin Chen, Nikolaos Spyrou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 18, 2017
Prospective, Randomized, Double-Blind, Phase III Clinical Trial of Anti-T-Lymphocyte Globulin to Assess Impact on Chronic Graft-Versus-Host Disease-Free Survival in Patients Undergoing HLA-Matched Unrelated Myeloablative Hematopoietic Cell TransplantationRobert J Soiffer, Haesook T Kim, Joseph McGuirk, et al.
The New England Journal of Medicine|June 21, 2023
Post-Transplantation Cyclophosphamide-Based Graft-versus-Host Disease ProphylaxisJavier Bolaños-Meade, Mehdi Hamadani, Juan Wu, et al.
Transplantation and Cellular Therapy|September 2, 2024
Differences in Acute Graft-Versus-Host Disease (GVHD) Severity and Its Outcomes Between Black and White PatientsCarlos A Ortega Rios, Muna Qayed, Aaron M Etra, et al.
Blood Advances|April 20, 2022
Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratificationAaron Etra, Stephanie Gergoudis, George Morales, et al.
Leukemia|February 6, 2020
Disease risk and GVHD biomarkers can stratify patients for risk of relapse and nonrelapse mortality post hematopoietic cell transplantMina D Aziz, Jay Shah, Urvi Kapoor, et al.
Blood Advances|April 30, 2025
Impact of Post-Transplant Cyclophosphamide-Based GVHD Prophylaxis in Patients 70 years and Older: An Update from BMT CTN 1703Sameem M Abedin, Michael J Martens, Javier Bolaños-Meade, et al.
JCI Insight|August 24, 2018
An early-biomarker algorithm predicts lethal graft-versus-host disease and survivalMatthew J Hartwell, Umut Özbek, Ernst Holler, et al.
Pageof 15